Latest news with #Dr.Reddy's
New Indian Express
31-07-2025
- Business
- New Indian Express
Indian equity markets end lower on Thursday amid sudden US tariff concerns
CHENNAI: Indian equity markets ended lower on Thursday, July 31, weighed down by a sudden tariff announcement by former US President Donald Trump. The BSE Sensex closed at 81,185.58, falling 296.28 points or 0.36%, while the NSE Nifty 50 settled at 24,768.35, down 86.70 points or 0.35%. Markets opened sharply in the red after Trump declared a 25% tariff on Indian imports, citing India's energy and defense ties with Russia. The move sparked heavy selling across export-oriented sectors including pharmaceuticals, textiles, and auto components. Stocks such as Dr. Reddy's and Sun Pharma fell up to 3%, while smaller exporters like Avanti Feeds and Apex Frozen Foods dropped over 6%. Within the first 15 minutes of trade, the Sensex lost as much as 786 points and the Nifty slipped over 212 points, leading to a market capitalisation erosion of nearly ₹5 lakh crore. However, equities rebounded from the day's lows by midday as investors bought into domestic-facing sectors like FMCG, banks, and media. Stocks like HUL, ITC, and Jio Financial Services helped cushion losses.
Business Upturn
31-07-2025
- Business
- Business Upturn
Why Dr. Reddy's shares are down nearly 2% today? Explained
By Aditya Bhagchandani Published on July 31, 2025, 09:44 IST Shares of Dr. Reddy's Laboratories Ltd dropped nearly 2% to ₹1,269.70 in early trade on Wednesday, reacting sharply to the overnight announcement by former U.S. President Donald Trump regarding the imposition of 25% tariffs on Indian exports to the United States. The move includes a yet-unspecified penalty for India's continued energy and defense dealings with Russia. The stock was among the worst-hit in the pharmaceutical space as investors digested the potential impact on generic drug exports, which constitute a major portion of India's pharmaceutical trade with the U.S. Pharma Exports at Risk? The United States is a critical market for Indian drugmakers. In fact, Dr. Reddy's derives 46% of its revenue from the U.S., making it highly sensitive to any changes in trade policy. While pharmaceuticals are currently exempt from the reciprocal tariff list (announced in April), officials from the White House confirmed to CNBC-TV18 that these exemptions may soon be lifted. The Department of Commerce's Section 232 investigation into Indian generic drug exports has now concluded, and according to Trump's latest statement, tariffs on pharma 'are coming soon.' Currently, India pays zero tariffs on generic drug exports to the U.S. If the proposed 25% tariff is applied to this sector, Indian companies may have to choose between: Passing the cost onto U.S. consumers , making Indian generics less price-competitive Reevaluating U.S. portfolios , withdrawing lower-margin or loss-making products Manufacturing in the U.S., which may offer no cost advantage for generics Broader Impact Across the Pharma Space Besides Dr. Reddy's, stocks likely to remain under pressure include: Sun Pharma (33% U.S. exposure) Aurobindo Pharma (45%) Gland Pharma (53%) Divi's Laboratories Cipla, Lupin, and Biocon Who Might Buck the Trend? Pharma firms and healthcare providers with a domestic business focus or minimal U.S. exposure may remain resilient: Ajanta Pharma, Eris Lifesciences, Torrent Pharma Apollo Hospitals, Fortis Healthcare, Aster DM Diagnostics players like Dr. Lal Pathlabs, Metropolis Final Word Though Indian pharma exports are not yet officially included in the tariff list, Trump's statements have created uncertainty for the sector. Until there is clarity from the U.S. Trade Representative or India's Commerce Ministry, investor sentiment around high U.S.-exposed pharma names may remain volatile. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
24-07-2025
- Business
- Business Upturn
India and UK sign free trade agreement; Here are the key companies that benefit from the FTA
India and the UK have officially signed a major Free Trade Agreement (FTA), marking a new chapter in their economic partnership. The deal, finalized on Thursday in the presence of Indian Prime Minister Narendra Modi and UK Prime Minister Keir Starmer, is expected to boost bilateral trade by nearly $34 billion annually. This FTA—billed as the UK's most significant since Brexit—promises to reduce tariffs, improve market access, and enhance investment opportunities across key sectors. Indian sectors like pharmaceuticals, financial services, textiles, IT, and renewable energy are likely to be major beneficiaries. Companies that may see direct gains include: Sun Pharma, Dr. Reddy's : Lower UK tariffs can boost exports of generic drugs. Infosys, TCS, Wipro : Easier mobility and service access could benefit Indian IT majors. Aditya Birla, Welspun, Arvind : Textile and apparel firms are expected to gain from duty-free access. Reliance, ReNew Power : Clean energy firms may benefit from joint initiatives and UK green investments. ICICI Bank, HDFC Bank: Eased regulations in financial services could open more global banking channels. The full impact will unfold as more details emerge in the joint statement scheduled later today, but early signs point to a strong economic and strategic boost for both nations. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
CNBC
24-07-2025
- Business
- CNBC
This Indian pharma company sees a big opportunity in generic versions of weight-loss drugs
Dr. Reddy 's Laboratories is betting big on a new wave of growth fueled by a global demand for weight-loss drugs — by launching its own lower-cost version of semaglutide, the blockbuster ingredient behind Wegovy and Ozempic. The Indian pharmaceutical company plans to launch its generic version of the drug in 87 countries by 2026, CEO Erez Israeli said. "This is a very, very important product because it's becoming more and more as a first-line therapy for type 2 diabetes, as well as for weight loss," he told CNBC. In 2022, more than 2.5 billion adults globally were overweight, of whom 890 million were obese, according to the World Health Organization . The International Diabetes Foundation says that around 589 million people worldwide have diabetes, of whom over 90% have type 2 diabetes. Their reported effectiveness in treating obesity and diabetes had led to a supply crunch for semaglutide, with major pharmaceutical giants such as Novo Nordisk and Eli Lilly scrambling to meet the demand. That supply gap, combined with expiring patents in India and Brazil, has opened up an opportunity for Dr. Reddy's to be a first mover in dozens of emerging markets. "The reason that so many markets can be open next year is because in many of these markets, the product was never launched due to capacity constrained by the innovator," Israeli said. "We have a chance to bring the product for the first time to these countries." Novo Nordisk is behind brands like Wegovy, which is used for weight loss only, and Ozempic and Rybelsus, which are treatments for type 2 diabetes. Eli Lily owns brands such as Tirzepatide, Mounjaro and Zepbound. Dr. Reddy's expects its product to be a significant contributor to revenue over the coming years, with Israeli noting: "It is going to be an important product for us. We can certainly see it is growing at the pace to get to hundreds of millions of dollars in revenue." Goldman Sachs had previously projected that the GLP-1 market could exceed $100 billion in annual sales by 2030 . However, high costs and limited availability have made access to these drugs largely concentrated in wealthier countries. Dr. Reddy's is not just planning to launch its generic version of the drug in 2026, but is already preparing for launches in countries that may open up in 2027 or 2028. The company is also eyeing additional GLP-1 generic products in the future. That market share may be easier to capture in some countries where Dr. Reddy's could be the only player—at least temporarily. "It could be a situation in some markets where we'll be the main one, or the only one for a certain period of time until the others will come." Crucially, Israeli believes that broader access to generics will lower the cost of GLP-1 and improve affordability in markets where it's still an "out-of-pocket" product for most people. DRREDDY-IN YTD line Dr Reddy's falls short of quarterly profit expectations The pharmaceutical company missed quarterly profit expectations on Wednesday, with its net profit increasing by 2% to 14.18 billion rupees ($164.2 million), below analysts' estimate of 14.94 billion rupees, according to LSEG data. While the company is looking outward, Dr. Reddy's continues to operate in competitive markets like the U.S., where its product portfolio is evolving. Israeli also acknowledged the crowded nature of the U.S. generics market. "The business model in the United States is actually, in a way, that you have multiple competitors on every product. This is the nature of the business. It has its opportunities as well as its risks."
Business Upturn
04-07-2025
- Business
- Business Upturn
Nifty top gainers today, July 4: Bajaj Finance, Dr. Reddy's, Infosys, Hindustan Unilever, ICICI Bank and more
Indian equity benchmarks ended the July 4 trading session on a positive note, despite intraday volatility. The BSE Sensex gained 193.42 points, or 0.23%, to close at 83,432.89. Meanwhile, the NSE Nifty 50 rose by 55.70 points, or 0.22%, ending at 25,461.00. Several heavyweight Nifty 50 stocks stood out by posting decent gains, led by Bajaj Finance, Dr. Reddy's and Infosys. Below is a detailed look at the top gainers of the Nifty 50 (as per Trendline) for the day. Nifty 50 Top Gainers on July 4 Bajaj Finance closed at ₹926.00, up by 1.7%. Dr. Reddy's Laboratories ended at ₹1,310.00, gaining 1.5%. Infosys settled at ₹1,639.70, rising by 1.3%. Hindustan Unilever closed at ₹2,341.30, up 1.2%. ICICI Bank ended the session at ₹1,443.00, also up 1.2%. Wipro rose 0.9% to close at ₹269.50. UltraTech Cement finished at ₹12,505.00, also gaining 0.9%. HCL Technologies closed at ₹1,725.90, higher by 0.8%. Reliance Industries ended at ₹1,528.10, up 0.7%. Hero MotoCorp closed at ₹4,337.80, advancing 0.6%. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Bajaj FinanceDr Reddy'sHindustan UnileverICICI BankInfosysNifty Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
